Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; ba... Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. Show more
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab) PR Newswire SPRING HOUSE, Pa., Dec. 2, 2024 Applications filed for TREMFYA® to treat...
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor PR Newswire SPRING HOUSE, Pa., Nov...
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting PR Newswire RARITAN, N.J., Nov. 19, 2024 More...
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results PR Newswire SPRING HOUSE, Pa...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study PR Newswire WASHINGTON, Nov. 14, 2024 Adults with...
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease PR...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma PR...
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR Newswire SPRING HOUSE, Pa., Nov. 7, 2024 New data for investigational nipocalimab in...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.675 | -1.07869654817 | 155.28 | 156.63 | 153.11 | 5613722 | 154.89297508 | CS |
| 4 | -4.065 | -2.57816959472 | 157.67 | 160.85 | 150.76 | 7894706 | 154.85097907 | CS |
| 12 | -14.015 | -8.36117408424 | 167.62 | 168.46 | 150.76 | 6460591 | 159.61845003 | CS |
| 26 | 6.355 | 4.31578947368 | 147.25 | 168.85 | 143.88 | 6655023 | 157.25752496 | CS |
| 52 | -4.345 | -2.75087052865 | 157.95 | 168.85 | 143.13 | 7058633 | 155.96872777 | CS |
| 156 | -4.295 | -2.72007599747 | 157.9 | 186.69 | 143.13 | 8526923 | 164.24695788 | CS |
| 260 | 16.695 | 12.1941421372 | 136.91 | 186.69 | 109.16 | 8115838 | 159.95621489 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
